Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies
Tóm tắt
While the advantages of the two basal insulin analogues, glargine and detemir, over neutral protamine Hagedorn are well established, the relative merit of the two compared with each other has been a matter of some controversy. The two analogues are popularly perceived to differ from each other in their pharmacodynamic (PD) profiles, in particular with regard to ‘flatness’ and duration of action. The aim of this review, therefore, is to give a complete overview on the available PD data of both analogues as derived with the glucose clamp technique. In order to improve parity across studies, a common definition for duration of action (time from injection to plasma glucose >8.3 mmol/l) was applied and study data were recalculated when necessary. Despite differences in methodological details, the results of most clamp studies were very consistent. Glargine and detemir both typically show a gentle rise and fall in glucose‐lowering action over time. Duration of action with both analogues is dose dependent, but in the clinically relevant range of 0.35–0.8 U/kg it is close to 24 h in people with type 1 diabetes and in excess of this in people with type 2 diabetes. While both analogues seem to be very similar with regard to the mean shape of their PD profile and duration of action, detemir shows less within‐subject variability in its metabolic effect. These findings in experimental glucose clamp studies are consistent with observations in clinical trials and support routine once daily use with either analogue, in particular in people with type 2 diabetes.
Từ khóa
Tài liệu tham khảo
Rosskamp RH, 1999, Long‐acting insulin analogs, Diabetes Care, 22, B109
EMEA/CPMP.Note for Guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus (London 30 May 2002 CPMP/EWP/1080/00). Available from URL:http://www.emea.eu.int/pdfs/human/ewp/108000en.pdf. Accessed 10 April 2007.
Porcellati F, 2006, Pharmacokinetics and ‐dynamics of therapeutic doses of the ‘long‐acting’ insulin analogues glargine and detemir at steady‐state in type 1 diabetes, Diabet Med, 23, 341
Heinemann L, 1998, Pharmacokinetics and metabolism of insulin lispro, Insulin Lispro: A New Rapid-acting Insulin Analog, Chapter III. Drugs Today (Barc), 34, 23
Nosek L, 2003, No increase in the duration of action with rising doses of insulin aspart, Diabetes, 52, 551
Lauritzen T, 1985, Pharmacokinetic and clinical aspects of intensified subcutaneous insulin therapy, Dan Med Bull, 32, 104
Dornhorst A, 2006, Initiating insulin detemir improves glycaemic control without weight gain in OAD‐treated, insulin naive patients with type 2 diabetes: results from the PREDICTIVE™ study, Diabet Med, 23, 136
Tsur A, 2006, Switching from premix insulin to BB therapy with insulin detemir and insulin aspart improves glycaemic control and reduces hypoglycaemia, without weight gain, in type 2 patients: 3‐month results from the PREDICTIVE™ study, Diabet Med, 23, 347
Pieber TR, 2005, Insulin therapy in type 1 diabetes – insulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetes, Diabetologia, 48
Porcellati F, 2005, Optimized use of insulin glargine in intensive treatment of type 1 diabetes mellitus: benefits and a new question, Diabetes, 54, 524
Le Floch J, 2006, Interim results of a French multi‐centre trial comparing insulin detemir once daily vs. twice daily in people with type 1 diabetes: the ADAPT study, Diabet Med, 23
Gallwitz B, 2006, Switching from a human to an insulin analogue BB regimen with insulin detemir/insulin aspart improves glycaemic control and reduces hypoglycaemic episodes in type 1 patients: results from the PREDICTIVETM study, Diabet Med, 23
Rosenstock J, 2006, Insulin detemir added to oral anti‐diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain, Diabetes, 55, 555